Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy

Commentary
Video

Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.

The cost of anti-cancer therapies varies by type, but most are considered expensive and can cost upwards of $100,000. The oftentimes negative impact of this cost affects the patient in many ways, whether it is due to the financial strain or the mental effect. CancerNetwork® spoke with Rachel Greenup, MD, MPH, who, among her many specialties, focuses on ways to mitigate the financial burden that cancer therapy has on patients, as well as their loved ones.

According to Greenup, MD, MPH, a multi-pronged approach is needed to reduce the financial toxicity often associated with breast cancer treatment, as well as other types of cancer treatment. One of the first things that care providers need to establish is that patients should not feel shame for being unable to afford the therapies, as many patients struggle with the same thing.

Notably, delaying discussions about financial toxicity can often exacerbate the problem, as case managers and social workers may have resources or grants that could reduce the burden. By delaying the discussion, the debts and bills can rack up and become too great of a hurdle to overcome.

Greenup also emphasized the importance of financial navigation, which includes reducing the number of times a patient is forced to attend appointments because time spent at an appointment is time not spent at a job or making money.

Greenup is a professor of surgery, the section chief of Breast Surgery, and the co-director of the Center for Breast Cancer at Smilow Cancer Hospital of Yale School of Medicine.

Transcript:

Financial toxicity describes the distress of high cancer treatment costs for [patients] going through oncology treatment, breast cancer or otherwise. It’s a multi-pronged approach [that is] needed to reduce or eliminate financial toxicity. The first thing patients and families need to know is that this is a big struggle for many people, and there should be no shame in asking for help with the affordability of care. Many case managers and social workers have access to either institutional- or hospital-level grants, or to regional nonprofit organizations that can also help defray the cost of care. Financial navigation is important, [like] helping patients think about coordinating their care so they’re not adding additional appointments or coming back and forth from the hospital many times, which can obviously cut into the ability to work and get paid for that work. I encourage patients and families to ask, to first say, “Is there someone I can talk to about affording cancer treatment?” and to not feel shame. Unfortunately, many people don’t ask for help until they’re in crisis, at which point the bills are astronomically high, and the solution or the fix for those high costs is much more difficult to find.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Related Content